Seeking Alpha

FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic

HOUSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (FBLG), ("FibroBiologics") and Charles River Laboratories (“Charles River”), a leading, global ...
Seeking Alpha

NurExone Biologic Secures Master Cell Bank

TORONTO and HAIFA, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CA), (OTCQB: NRXBF), (Germany: J90) ("NurExone" or the "Company"), a developer of exosome-based therapies for ...
Nasdaq

FibroBiologics Completes Master Cell Bank for CYWC628 in Collaboration with Charles River Laboratories

FibroBiologics, Inc. has announced the completion of its proprietary master cell bank, which will support its upcoming clinical trials. Developed in partnership with Charles River Laboratories and ...
Healio

Fibroblast technology developed for diabetic foot ulcers, chronic wounds

Please provide your email address to receive an email when new articles are posted on . A master cell bank has been completed for a product that will utilize fibroblasts to treat chronic wounds.
Nasdaq

FibroBiologics, Charles River Finalize Master Cell Bank For CYWC628 Diabetic Foot Ulcer Trial

(RTTNews) - FibroBiologics, Inc. (FBLG) and Charles River Laboratories have announced the completion of the master cell bank for CYWC628, a fibroblast-based therapy targeting diabetic foot ulcers. The ...
Longview News-Journal

Cellipont Bioservices and Secretome Therapeutics Partner for cGMP Manufacturing for Master Cell Bank for Lead Asset STM-01

THE WOODLANDS, Texas and DALLAS, Jan. 22, 2025 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a ...